aristolochic acid i has been researched along with Fibrosis in 70 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, the effect of ethyl acetate extract of Nan Mu Xiang (NMX) on cardiac fibrosis was assessed in vitro by cultured adult rat cardiac fibroblasts with angiotensin II (AngII) stimulation, and in vivo by rats with abdominal aorta constriction (AAC)." | 7.80 | Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways. ( Chen, S; Cheng, Z; Li, C; Li, D; Li, H; Liu, P; Ma, Y; Peng, J; Shao, W; Shen, X; Yin, S; You, Y; Yu, Y; Zhou, C, 2014) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 7.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 5.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 5.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "With the aim to explore the possibility to generate a zebrafish model of renal fibrosis, in this study the fibrogenic renal effect of aristolochic acid I (AAI) after immersion was assessed." | 3.96 | Nephrotoxic Effects in Zebrafish after Prolonged Exposure to Aristolochic Acid. ( de Witte, PA; Giusti, A; Ny, A; Wang, X, 2020) |
| " In this study, the effect of ethyl acetate extract of Nan Mu Xiang (NMX) on cardiac fibrosis was assessed in vitro by cultured adult rat cardiac fibroblasts with angiotensin II (AngII) stimulation, and in vivo by rats with abdominal aorta constriction (AAC)." | 3.80 | Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways. ( Chen, S; Cheng, Z; Li, C; Li, D; Li, H; Liu, P; Ma, Y; Peng, J; Shao, W; Shen, X; Yin, S; You, Y; Yu, Y; Zhou, C, 2014) |
| "Our findings demonstrate the first that AA could induce secretion and expression of fibrogenic leptin in kidney fibroblasts, which reveal potential involvement of leptin in the progression of kidney fibrosis in aristolochic acid nephropathy." | 3.77 | The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast. ( Hsu, SL; Lee, TC; Lin, TC; Yang, CS, 2011) |
| "Early renal injury via renal interstitial fibrosis was induced in rats by administration of aristolochic acid I (AAI) solution intragastrically for 8 weeks." | 3.77 | Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. ( Cheng, XH; Lin, RC; Mao, JR; Sun, WJ; Zhang, L; Zhang, Y; Zhao, YY, 2011) |
| "To study the protective effects of Yishen Ruanjian Power (YRP) on renal interstitial fibrosis in rats with chronic aristolochic acid induced nephropathy (CAAN)." | 3.73 | [Protective effects of yishen ruanjian power on renal interstitial fribrosis in chronic aristolochic acid induced nephropathy rat model]. ( Chen, YP; Dong, H; Yang, YF; Zhang, C, 2005) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 3.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "Renal failure was in progression since Pcreat was 2." | 2.68 | Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. ( Abramowicz, D; Depierreux, M; Tielemans, C; Vanherweghem, JL, 1996) |
| " However, the same AA-IVa dosage exhibited almost no nephrotoxicity and does not trigger RIF." | 1.91 | Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity. ( Han, J; Li, C; Liang, A; Liu, C; Liu, S; Meng, J; Pan, C; Tang, X; Tian, J; Wang, D; Wang, F; Wang, L; Wang, Y; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023) |
| "Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases." | 1.62 | Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice. ( Abe, E; Atobe, Y; Azushima, K; Funakoshi, K; Kanaoka, T; Kinguchi, S; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Uneda, K; Urate, S; Wakui, H; Yamaji, T; Yamashita, A, 2021) |
| "Renal fibrosis is a progressive pathological process that eventually leads to end-stage renal failure with limited therapeutic options." | 1.56 | Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro. ( He, D; Hu, D; Lin, T; Liu, B; Liu, X; Long, C; Shen, L; Wei, G; Xiang, H; Xu, T; Yu, Y; Zhang, D; Zhang, Y; Zhou, Y, 2020) |
| "Renal interstitial fibrosis is one of the most typical features of AAN." | 1.48 | The potential role of aquaporin 1 on aristolochic acid I induced epithelial mesenchymal transition on HK-2 cells. ( Li, J; Li, Y; Mao, Y; Peng, X; Yu, F; Zhang, M; Zhang, X, 2018) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 1.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "Interstitial fibrosis is an inevitable outcome of all kinds of progressive chronic kidney disease (CKD)." | 1.38 | Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. ( Chen, G; Chen, H; Liu, F; Liu, H; Peng, Y; Sun, L; Wang, C, 2012) |
| "Treatment with probenecid prevented increased plasma creatinine and tubulointerstitial injuries, and reduced both the extent and the severity of ultrastructural lesions induced by aristolochic acid, such as the loss of brush border, mitochondrial edema, and the disappearance of mitochondrial crests." | 1.38 | Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. ( Antoine, MH; Arlt, VM; Baudoux, TE; De Prez, EG; Goujon, JM; Nortier, JL; Pozdzik, AA; Quellard, N, 2012) |
| " Results revealed that chronic administration of aristolochic acid (AA) resulted in a severe AAN characterized by progressive renal dysfunction and tubulointerstitial fibrosis including epithelial-mesenchymal transition (EMT) in Smad3 WT mice, but not in Smad3 KO mice, suggesting a critical role for Smad3 in the development of AAN." | 1.36 | Mechanism of chronic aristolochic acid nephropathy: role of Smad3. ( Chung, AC; Fu, P; Huang, XR; Lai, KN; Lan, HY; Liu, F; Zhou, L, 2010) |
| " To distinguish the component(s) of AA responsible for these varied toxic effects, we administered 2." | 1.34 | Selective toxicity of aristolochic acids I and II. ( Dong, H; Grollman, AP; Miller, F; Shibutani, S; Suzuki, N; Ueda, S, 2007) |
| " In the present study, the effects of a chronic intake of AA given as a single drug was evaluated through renal histology and function in rabbits." | 1.31 | Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? ( Bernard, AM; Cosyns, JP; Dehoux, JP; Goebbels, RM; Guiot, Y; Robert, A; van Ypersele de Strihou, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.86) | 18.2507 |
| 2000's | 21 (30.00) | 29.6817 |
| 2010's | 29 (41.43) | 24.3611 |
| 2020's | 18 (25.71) | 2.80 |
| Authors | Studies |
|---|---|
| Urate, S | 3 |
| Wakui, H | 3 |
| Azushima, K | 2 |
| Yamaji, T | 3 |
| Suzuki, T | 3 |
| Abe, E | 3 |
| Tanaka, S | 3 |
| Taguchi, S | 2 |
| Tsukamoto, S | 2 |
| Kinguchi, S | 3 |
| Uneda, K | 1 |
| Kanaoka, T | 1 |
| Atobe, Y | 1 |
| Funakoshi, K | 1 |
| Yamashita, A | 2 |
| Tamura, K | 3 |
| Kamimura, D | 1 |
| Sasaki, K | 1 |
| Terker, AS | 1 |
| Tang, J | 1 |
| Cao, S | 1 |
| Arroyo, JP | 1 |
| Niu, A | 1 |
| Wang, S | 1 |
| Fan, X | 1 |
| Zhang, Y | 5 |
| Bennett, SR | 1 |
| Zhang, MZ | 1 |
| Harris, RC | 2 |
| Wang, X | 3 |
| Jia, P | 1 |
| Ren, T | 1 |
| Zou, Z | 1 |
| Xu, S | 1 |
| Shi, Y | 2 |
| Bao, S | 1 |
| Li, Y | 2 |
| Fang, Y | 2 |
| Ding, X | 2 |
| Xian, Z | 1 |
| Tian, J | 1 |
| Zhao, Y | 4 |
| Yi, Y | 1 |
| Li, C | 3 |
| Han, J | 1 |
| Wang, Y | 2 |
| Wang, L | 1 |
| Liu, S | 1 |
| Pan, C | 1 |
| Liu, C | 1 |
| Wang, D | 1 |
| Meng, J | 1 |
| Tang, X | 1 |
| Wang, F | 1 |
| Liang, A | 1 |
| Sun, MX | 1 |
| Qiao, FX | 1 |
| Xu, ZR | 1 |
| Liu, YC | 1 |
| Xu, CL | 1 |
| Wang, HL | 2 |
| Qi, ZQ | 1 |
| Liu, Y | 3 |
| Ren, J | 3 |
| Rudemiller, NP | 1 |
| Wen, Y | 1 |
| Lu, X | 1 |
| Privratsky, JR | 1 |
| Crowley, SD | 1 |
| Chen, SM | 2 |
| Lin, CE | 2 |
| Chen, HH | 1 |
| Cheng, YF | 1 |
| Cheng, HW | 1 |
| Imai, K | 1 |
| Giusti, A | 1 |
| Ny, A | 1 |
| de Witte, PA | 1 |
| Chang, JF | 1 |
| Hsieh, CY | 1 |
| Lu, KC | 1 |
| Chen, YW | 1 |
| Liang, SS | 1 |
| Lin, CC | 1 |
| Hung, CF | 1 |
| Liou, JC | 1 |
| Wu, MS | 1 |
| Yu, Y | 2 |
| Hu, D | 1 |
| Zhou, Y | 1 |
| Xiang, H | 1 |
| Liu, B | 1 |
| Shen, L | 1 |
| Long, C | 1 |
| Liu, X | 1 |
| Lin, T | 1 |
| He, D | 1 |
| Xu, T | 1 |
| Zhang, D | 1 |
| Wei, G | 1 |
| Zhao, H | 1 |
| Jiang, N | 1 |
| Han, Y | 1 |
| Yang, M | 1 |
| Gao, P | 1 |
| Xiong, X | 1 |
| Xiong, S | 1 |
| Zeng, L | 1 |
| Xiao, Y | 2 |
| Wei, L | 1 |
| Li, L | 6 |
| Yang, J | 1 |
| Tang, C | 1 |
| Xiao, L | 1 |
| Liu, F | 3 |
| Sun, L | 2 |
| Xue, N | 1 |
| Zhao, S | 1 |
| Ishii, T | 1 |
| Kumagae, T | 1 |
| Kobayashi, R | 1 |
| Haruhara, K | 1 |
| Nakamura, T | 2 |
| Kobayashi, S | 1 |
| Lin, PY | 1 |
| Yang, WC | 1 |
| Huang, YS | 1 |
| Lin, TY | 1 |
| Chen, CM | 1 |
| Chen, HS | 1 |
| Lee, JA | 1 |
| Tao, S | 1 |
| Guo, F | 1 |
| Liu, J | 1 |
| Huang, R | 1 |
| Tan, Z | 1 |
| Zeng, X | 1 |
| Ma, L | 1 |
| Fu, P | 2 |
| Lu, YA | 1 |
| Liao, CT | 1 |
| Raybould, R | 1 |
| Talabani, B | 1 |
| Grigorieva, I | 1 |
| Szomolay, B | 1 |
| Bowen, T | 1 |
| Andrews, R | 1 |
| Taylor, PR | 1 |
| Fraser, D | 1 |
| Kocic, G | 1 |
| Gajic, M | 1 |
| Tomovic, K | 1 |
| Hadzi-Djokic, J | 1 |
| Anderluh, M | 1 |
| Smelcerovic, A | 1 |
| Leung, JY | 1 |
| Wilson, HL | 1 |
| Voltzke, KJ | 1 |
| Williams, LA | 1 |
| Lee, HJ | 1 |
| Wobker, SE | 1 |
| Kim, WY | 1 |
| Zeniya, M | 1 |
| Mori, T | 1 |
| Yui, N | 1 |
| Nomura, N | 1 |
| Mandai, S | 1 |
| Isobe, K | 1 |
| Chiga, M | 1 |
| Sohara, E | 1 |
| Rai, T | 1 |
| Uchida, S | 1 |
| Li, J | 2 |
| Zhang, M | 1 |
| Mao, Y | 1 |
| Zhang, X | 2 |
| Peng, X | 1 |
| Yu, F | 1 |
| Honarpisheh, M | 1 |
| Foresto-Neto, O | 1 |
| Steiger, S | 1 |
| Kraft, F | 1 |
| Koehler, P | 1 |
| von Rauchhaupt, E | 1 |
| Potempa, J | 1 |
| Adamowicz, K | 1 |
| Koziel, J | 1 |
| Lech, M | 1 |
| Song, MK | 1 |
| Lee, JH | 1 |
| Ryoo, IG | 1 |
| Lee, SH | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Sun, X | 1 |
| Wei, W | 1 |
| Liang, Y | 3 |
| Wang, M | 1 |
| Gui, Y | 1 |
| Xue, X | 2 |
| Dai, C | 1 |
| Li, S | 1 |
| Mariappan, N | 1 |
| Megyesi, J | 1 |
| Shank, B | 1 |
| Kannan, K | 1 |
| Theus, S | 1 |
| Price, PM | 1 |
| Duffield, JS | 1 |
| Portilla, D | 1 |
| Scarpellini, A | 1 |
| Huang, L | 1 |
| Burhan, I | 1 |
| Schroeder, N | 1 |
| Funck, M | 1 |
| Johnson, TS | 1 |
| Verderio, EA | 1 |
| Novitskaya, T | 1 |
| McDermott, L | 1 |
| Zhang, KX | 1 |
| Chiba, T | 1 |
| Paueksakon, P | 1 |
| Hukriede, NA | 1 |
| de Caestecker, MP | 1 |
| Bai, Y | 3 |
| Lu, H | 3 |
| Hu, L | 1 |
| Hong, D | 1 |
| Ding, L | 1 |
| Chen, B | 3 |
| Zhang, G | 1 |
| Wu, C | 1 |
| Lin, C | 1 |
| Antoine, MH | 2 |
| Debelle, F | 2 |
| Piccirilli, J | 1 |
| El Kaddouri, F | 1 |
| Declèves, AE | 1 |
| De Prez, E | 2 |
| Husson, C | 1 |
| Mies, F | 1 |
| Bourgeade, MF | 2 |
| Nortier, JL | 6 |
| Neelisetty, S | 1 |
| Alford, C | 1 |
| Reynolds, K | 1 |
| Woodbury, L | 1 |
| Nlandu-Khodo, S | 1 |
| Yang, H | 1 |
| Fogo, AB | 1 |
| Hao, CM | 1 |
| Zent, R | 1 |
| Gewin, L | 1 |
| Samarakoon, R | 1 |
| Helo, S | 1 |
| Dobberfuhl, AD | 1 |
| Khakoo, NS | 1 |
| Falke, L | 1 |
| Overstreet, JM | 1 |
| Goldschmeding, R | 1 |
| Higgins, PJ | 1 |
| Zhao, YY | 2 |
| Cheng, XL | 1 |
| Wei, F | 1 |
| Bai, X | 1 |
| Lin, RC | 2 |
| Vaziri, ND | 1 |
| Hong, W | 1 |
| Zhang, Z | 1 |
| Shen, H | 1 |
| Lu, Y | 1 |
| Li, H | 2 |
| Ren, X | 1 |
| Wu, G | 1 |
| Hamano, Y | 1 |
| Aoki, T | 1 |
| Shirai, R | 1 |
| Hatano, M | 1 |
| Kimura, R | 1 |
| Ogawa, M | 1 |
| Yokosuka, O | 1 |
| Ueda, S | 2 |
| Zhou, L | 1 |
| Huang, XR | 1 |
| Chung, AC | 1 |
| Lai, KN | 1 |
| Lan, HY | 1 |
| Shaohua, Z | 1 |
| Ananda, S | 1 |
| Ruxia, Y | 1 |
| Liang, R | 1 |
| Xiaorui, C | 1 |
| Liang, L | 1 |
| Pozdzik, AA | 4 |
| Berton, A | 1 |
| Schmeiser, HH | 2 |
| Missoum, W | 1 |
| Decaestecker, C | 3 |
| Salmon, IJ | 4 |
| Vanherweghem, JL | 6 |
| Lin, TC | 1 |
| Lee, TC | 1 |
| Hsu, SL | 1 |
| Yang, CS | 1 |
| Chau, W | 1 |
| Ross, R | 1 |
| Li, JY | 1 |
| Yong, TY | 1 |
| Klebe, S | 1 |
| Barbara, JA | 1 |
| Fragiadaki, M | 1 |
| Witherden, AS | 1 |
| Kaneko, T | 1 |
| Sonnylal, S | 1 |
| Pusey, CD | 1 |
| Bou-Gharios, G | 1 |
| Mason, RM | 1 |
| Zhang, L | 1 |
| Mao, JR | 1 |
| Cheng, XH | 1 |
| Sun, WJ | 1 |
| Chen, G | 1 |
| Chen, H | 1 |
| Wang, C | 1 |
| Peng, Y | 1 |
| Liu, H | 1 |
| Baudoux, TE | 1 |
| Arlt, VM | 3 |
| De Prez, EG | 2 |
| Quellard, N | 1 |
| Goujon, JM | 1 |
| Nortier, J | 2 |
| Vienne, A | 1 |
| Salmon, I | 1 |
| Phillips, DH | 2 |
| Deschodt-Lanckman, M | 1 |
| Yang, L | 2 |
| Li, XM | 1 |
| Wang, HY | 1 |
| Gillerot, G | 1 |
| Goffin, E | 1 |
| Moulin, P | 1 |
| Cosyns, JP | 2 |
| Devuyst, O | 1 |
| Okada, H | 1 |
| Watanabe, Y | 1 |
| Inoue, T | 1 |
| Kobayashi, T | 1 |
| Kanno, Y | 1 |
| Shiota, G | 1 |
| Sugaya, T | 1 |
| Fukamizu, A | 1 |
| Suzuki, H | 1 |
| Wu, Y | 1 |
| Liu, Z | 1 |
| Hu, W | 1 |
| Zhang, C | 2 |
| Chen, YP | 2 |
| Yang, YF | 1 |
| Dong, H | 2 |
| Dong, HR | 1 |
| Qiu, CB | 1 |
| Li, X | 1 |
| Wang, H | 2 |
| Shibutani, S | 1 |
| Suzuki, N | 1 |
| Miller, F | 1 |
| Grollman, AP | 1 |
| Debelle, FD | 2 |
| Van den Branden, C | 1 |
| Verbeelen, D | 1 |
| Deschodt-Lanckman, MM | 3 |
| Husson, CP | 1 |
| Rogier, E | 1 |
| Zhu, H | 1 |
| Xie, T | 1 |
| Abramowicz, D | 1 |
| Tielemans, C | 1 |
| Depierreux, M | 1 |
| Stiborová, M | 1 |
| Frei, E | 1 |
| Breuer, A | 1 |
| Bieler, CA | 1 |
| Dehoux, JP | 1 |
| Guiot, Y | 1 |
| Goebbels, RM | 1 |
| Robert, A | 1 |
| Bernard, AM | 1 |
| van Ypersele de Strihou, C | 1 |
| Nishimagi, E | 1 |
| Kawaguchi, Y | 1 |
| Terai, C | 1 |
| Kajiyama, H | 1 |
| Hara, M | 1 |
| Kamatani, N | 1 |
| Zheng, F | 1 |
| Huang, Q | 1 |
| Garbar, CH | 1 |
| Vienne, AR | 1 |
| Lou, LL | 1 |
| Li, W | 2 |
| Zhou, BH | 1 |
| Chen, L | 1 |
| Weng, HZ | 1 |
| Zou, YH | 1 |
| Tang, GH | 1 |
| Bu, XZ | 1 |
| Yin, S | 2 |
| Shao, W | 1 |
| Li, D | 1 |
| Peng, J | 1 |
| Chen, S | 1 |
| Zhou, C | 1 |
| Cheng, Z | 1 |
| You, Y | 1 |
| Ma, Y | 1 |
| Liu, P | 1 |
| Shen, X | 1 |
| Jiang, H | 1 |
| Feng, JM | 1 |
| Du, GY | 3 |
| Zhou, SJ | 3 |
| Cu, HF | 2 |
| Wang, XR | 3 |
| Xiao, YQ | 3 |
| Cao, CY | 2 |
| Zhang, CY | 1 |
| Wu, ZL | 2 |
| Gao, SR | 2 |
| He, R | 2 |
| Hui, LQ | 2 |
| Liu, BY | 2 |
| Cui, HF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis[NCT03487861] | 1,000 participants (Anticipated) | Observational | 2017-08-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aristolochic acid i and Fibrosis
| Article | Year |
|---|---|
Purine adducts as a presumable missing link for aristolochic acid nephropathy-related cellular energy crisis, potential anti-fibrotic prevention and treatment.
Topics: Aristolochic Acids; DNA Adducts; Fibrosis; Humans; Purines | 2021 |
Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome.
Topics: Aristolochic Acids; Biopsy; Chromatography, High Pressure Liquid; CREST Syndrome; Disease Progressio | 2001 |
1 trial available for aristolochic acid i and Fibrosis
| Article | Year |
|---|---|
Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy.
Topics: Aristolochic Acids; Case-Control Studies; Disease Progression; Drugs, Chinese Herbal; Female; Fibros | 1996 |
67 other studies available for aristolochic acid i and Fibrosis
| Article | Year |
|---|---|
Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice.
Topics: Aging; Animals; Aristolochic Acids; beta-Galactosidase; Collagen; Cyclin-Dependent Kinase Inhibitor | 2021 |
Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy.
Topics: Albuminuria; Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Etanercept; Fibrosis; In | 2021 |
Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis.
Topics: Animals; Apoptosis; Aristolochic Acids; Cells, Cultured; Disease Models, Animal; DNA; DNA Mutational | 2022 |
MicroRNA-382 Promotes M2-Like Macrophage
Topics: Animals; Aristolochic Acids; Fibrosis; Kidney Diseases; Macrophage Activation; Macrophages; Mice; Mi | 2022 |
Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity.
Topics: Animals; Aristolochic Acids; Fibrosis; Kidney; Kidney Diseases; Mice; Proteomics; S100 Proteins; Sig | 2023 |
Aristolochic acid I exposure triggers ovarian dysfunction by activating NLRP3 inflammasome and affecting mitochondrial homeostasis.
Topics: Animals; Aristolochic Acids; Fibrosis; Homeostasis; Humans; Inflammasomes; Inflammation; Mice; Mitoc | 2023 |
The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy.
Topics: Animals; Apoptosis; Aristolochic Acids; Coculture Techniques; Disease Models, Animal; Epithelial Cel | 2020 |
Effect of prednisolone on glyoxalase 1 in an inbred mouse model of aristolochic acid nephropathy using a proteomics method with fluorogenic derivatization-liquid chromatography-tandem mass spectrometry.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; F | 2020 |
Nephrotoxic Effects in Zebrafish after Prolonged Exposure to Aristolochic Acid.
Topics: Acute Kidney Injury; Animals; Animals, Genetically Modified; Aristolochic Acids; Collagen; Fibrosis; | 2020 |
Therapeutic Targeting of Aristolochic Acid Induced Uremic Toxin Retention, SMAD 2/3 and JNK/ERK Pathways in Tubulointerstitial Fibrosis: Nephroprotective Role of Propolis in Chronic Kidney Disease.
Topics: Animals; Aristolochic Acids; Cresols; Disease Models, Animal; Epithelial-Mesenchymal Transition; Ext | 2020 |
Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro.
Topics: Animals; Aristolochic Acids; Cell Line; Coculture Techniques; Disease Models, Animal; Epithelial-Mes | 2020 |
Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF-1α.
Topics: Animals; Aristolochic Acids; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Epithelial Cells; Fib | 2020 |
Upregulation of miR-382 contributes to renal fibrosis secondary to aristolochic acid-induced kidney injury via PTEN signaling pathway.
Topics: Animals; Aristolochic Acids; Base Sequence; Cells, Cultured; Epithelial Cells; Epithelial-Mesenchyma | 2020 |
Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Humans; Kidney Tubules; Male; Mice; R | 2021 |
Evaluation of the nephrotoxicity and safety of low-dose aristolochic acid, extending to the use of Xixin (Asurum), by determination of methylglyoxal and d-lactate.
Topics: Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Female; Fibros | 2021 |
Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Biphenyl Compounds; Carcinogens; Disease Models, A | 2021 |
Single-Nucleus RNA Sequencing Identifies New Classes of Proximal Tubular Epithelial Cells in Kidney Fibrosis.
Topics: Animals; Aristolochic Acids; Cell Communication; Cell Movement; Cell Nucleus; Chromosome Mapping; Ep | 2021 |
Topics: Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Animals; Aristolochic Acids; Cell Cycle P | 2017 |
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.
Topics: Animals; Aristolochic Acids; Bortezomib; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; | 2017 |
The potential role of aquaporin 1 on aristolochic acid I induced epithelial mesenchymal transition on HK-2 cells.
Topics: Aquaporin 1; Aristolochic Acids; Cell Line; Epithelial-Mesenchymal Transition; Extracellular Signal- | 2018 |
Aristolochic acid I determine the phenotype and activation of macrophages in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Cisplatin; Disease Models, Animal; Female; Fibrosi | 2018 |
Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Topics: Animals; Aristolochic Acids; Cell Line; Extracellular Matrix; Fibrosis; Gene Expression Regulation; | 2019 |
Inhibition of 4E-BP1 phosphorylation promotes tubular cell escaping from G2/M arrest and ameliorates kidney fibrosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Aristolochic Acids; Cell Cycle; Cell Cycle | 2019 |
Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction.
Topics: Animals; Arginase; Aristolochic Acids; B7-2 Antigen; Collagen Type I; Collagen Type IV; Down-Regulat | 2013 |
Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
Topics: Animals; Aristolochic Acids; Fibrosis; GTP-Binding Proteins; Male; Mice; Mice, Inbred C57BL; Mice, K | 2014 |
A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Butyrates; Disease Models, Animal; Fibrosis; Histo | 2014 |
Effect of Sedum sarmentosum BUNGE extract on aristolochic acid-induced renal tubular epithelial cell injury.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Proliferation; Cells, Cultured; Drugs, Chinese Herbal; | 2014 |
Sedum sarmentosum Bunge extract exerts renal anti-fibrotic effects in vivo and in vitro.
Topics: Analysis of Variance; Animals; Aristolochic Acids; Cells, Cultured; DNA Primers; Drugs, Chinese Herb | 2014 |
Human bone morphogenetic protein-7 does not counteract aristolochic acid-induced renal toxicity.
Topics: Animals; Aristolochic Acids; beta Catenin; Bone Morphogenetic Protein 7; Cell Line; Fibronectins; Fi | 2015 |
Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells.
Topics: Actins; Animals; Aristolochic Acids; Cells, Cultured; Collagen Type I; Disease Models, Animal; Extra | 2015 |
Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Disea | 2015 |
Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Lipids; Male; M | 2015 |
Transforming growth factor-β1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury.
Topics: Animals; Aristolochic Acids; Cell Line; Disease Models, Animal; Disease Progression; Epithelial-Mese | 2016 |
TGF-beta1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AAI.
Topics: Actins; Animals; Aristolochic Acids; Benzamides; Cells, Cultured; Dioxoles; Down-Regulation; Epithel | 2008 |
Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Proliferation; Darbepoetin alfa; Disease Models, Animal | 2010 |
Mechanism of chronic aristolochic acid nephropathy: role of Smad3.
Topics: Animals; Aristolochic Acids; Cell Line; Collagen; Enzyme-Linked Immunosorbent Assay; Fibrosis; Gene | 2010 |
Fatal renal failure due to the Chinese herb "GuanMu Tong" (Aristolochia manshuriensis): autopsy findings and review of literature.
Topics: Acute Kidney Injury; Adult; Aristolochia; Aristolochic Acids; Drugs, Chinese Herbal; Epithelial Cell | 2010 |
Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity?
Topics: Adaptive Immunity; Adult; Aged; Aristolochic Acids; Case-Control Studies; Disease Progression; Drugs | 2010 |
The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast.
Topics: Animals; Aristolochic Acids; Carcinogens; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Disease | 2011 |
Nephropathy associated with use of a Chinese herbal product containing aristolochic acid.
Topics: Aged; Aristolochic Acids; Drugs, Chinese Herbal; Fatal Outcome; Fibrosis; Humans; Kidney Diseases; K | 2011 |
Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo.
Topics: Animals; Aristolochic Acids; Biomarkers; Blood Urea Nitrogen; Cadherins; Collagen Type I; Connective | 2011 |
Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Body Weight; Cholestenones; Fibrosis; Kidney; Kidn | 2011 |
Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts.
Topics: Animals; Aristolochic Acids; Cell Line; Cell Proliferation; Extracellular Matrix; Fibroblasts; Fibro | 2012 |
Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Atrophy; Biomarkers; Cell Proliferation; Cell Survival; Creatinine; Cyt | 2012 |
Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy.
Topics: Animals; Aristolochic Acids; Autoradiography; Body Weight; Creatinine; Dexfenfluramine; Disease Mode | 2003 |
[A comparative study of manchurian Dutchmanspipe and antibiotics induced acute tubular necrosis in renal cellular biological features].
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Aristolochia; Aristolochic Acids; Biopsy, Needle; Dru | 2003 |
Aristolochic acid nephropathy and the peritoneum: Functional, structural, and molecular studies.
Topics: Aged; Anti-Obesity Agents; Aquaporin 1; Aquaporins; Aristolochic Acids; Blood Group Antigens; Blotti | 2003 |
Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity.
Topics: Animals; Aristolochic Acids; Fibrosis; Growth Substances; Hepatocyte Growth Factor; Kidney; Kidney D | 2003 |
Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy.
Topics: Acute Disease; Adult; Aged; Aristolochic Acids; Cell Proliferation; Child; Chronic Disease; Disease | 2005 |
[Protective effects of yishen ruanjian power on renal interstitial fribrosis in chronic aristolochic acid induced nephropathy rat model].
Topics: Animals; Aristolochic Acids; beta 2-Microglobulin; Creatinine; Drugs, Chinese Herbal; Fibrosis; Kidn | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Mod | 2005 |
Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis.
Topics: Actins; Adult; Aristolochic Acids; Biomarkers; Biopsy; Connective Tissue Growth Factor; Disease Prog | 2007 |
Selective toxicity of aristolochic acids I and II.
Topics: Animals; Aristolochic Acids; Carcinogens; Cell Transformation, Neoplastic; DNA Adducts; Fibrosis; Ki | 2007 |
Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Proliferation; Chemokine CCL2; Collagen; Discoidin Doma | 2008 |
Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Fibrosis; Kidney; Kidney Failure, Chronic; Macr | 2008 |
Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury.
Topics: Animals; Aristolochic Acids; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Enzyme Inducti | 2008 |
Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; D | 1999 |
Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy?
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Drugs, Chinese Herbal; Enzyme Inhibitors; Femal | 2001 |
[Establishment of model of aristolochic acid-induced chronic renal interstitial fibrosis in rats].
Topics: Animals; Aristolochic Acids; Blood Urea Nitrogen; Body Weight; Carcinogens; Chronic Disease; Creatin | 2001 |
Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats.
Topics: Animals; Aristolochic Acids; Body Weight; Carcinoma, Transitional Cell; Dose-Response Relationship, | 2002 |
[Renal interstitial fibrosis and urotelial carcinomas after ingestion of a Chinese herb (Aristolochia fangchi)].
Topics: Anti-Obesity Agents; Aristolochia; Aristolochic Acids; Atrophy; Biomarkers; Carcinogens; Carcinoma, | 2002 |
(+)-Isobicyclogermacrenal and spathulenol from Aristolochia yunnanensis alleviate cardiac fibrosis by inhibiting transforming growth factor β/small mother against decapentaplegic signaling pathway.
Topics: Aldehydes; Animals; Aristolochia; Fibrosis; Humans; Male; Medicine, Chinese Traditional; Mice; Mothe | 2019 |
Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways.
Topics: Acetates; Animals; Aristolochia; Fibrosis; Heart Diseases; MAP Kinase Signaling System; Plant Extrac | 2014 |
Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1.
Topics: Animals; Aristolochia; Aristolochic Acids; Bone Marrow Cells; Down-Regulation; Female; Fibrosis; Hep | 2012 |
[Experimental study of chronic renal tubular-interstitial injury induced by radix aristolochiae fangchi extract in rats].
Topics: Acetylglucosaminidase; Animals; Aristolochia; Aristolochic Acids; Blood Urea Nitrogen; Body Weight; | 2005 |
[Experimental study of chronic renal tubular-interstitial injury induced by Radix Aristolochiae Fangchi Extract in rats].
Topics: Animals; Aristolochia; Aristolochic Acids; Blood Urea Nitrogen; Body Weight; Dose-Response Relations | 2005 |
[Study on transdifferentiation of renal tubular cells in rat chronic renal interstitial fibrosis induced by Radix Aristolochiae Fangchi Extract].
Topics: Actins; Animals; Aristolochia; Aristolochic Acids; Cell Transdifferentiation; Cytokines; Drugs, Chin | 2006 |